Patents by Inventor David F. McComsey

David F. McComsey has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Octahydro-cyclopentapyrrolyl antagonists of CCR2
    Patent number: 9024017
    Abstract: The present invention comprises compounds of Formula (I). wherein: R1, R2, R3, R4, R5, Z1 and Z2 are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula (I).
    Type: Grant
    Filed: July 16, 2013
    Date of Patent: May 5, 2015
    Assignee: Janssen Pharmaceutica NV
    Inventors: Chaozhong Cai, David F. McComsey, Zhihua Sui, Fu-An Kang
  • Co-therapy for the treatment of epilepsy and related disorders
    Patent number: 8853263
    Abstract: The present invention is directed to co-therapy for the treatment of epilepsy and related disorders comprising administering to a subject in need thereof, co-therapy with a therapeutically effective amount of a benzo-fused heterocycle sulfamide derivative and a therapeutically effective amount of one or more anticonvulsant and/or anti-epileptic agents.
    Type: Grant
    Filed: May 18, 2007
    Date of Patent: October 7, 2014
    Assignee: Janssen Pharmaceutica NV
    Inventors: Virginia L. Smith-Swintosky, David F. McComsey, Michael H. Parker, Allen B. Reitz, Bruce E. Maryanoff
  • Substituted sulfamide derivatives
    Patent number: 8815939
    Abstract: The present invention is directed to novel substituted sulfamide derivatives, pharmaceutical compositions containing said derivatives and the use of said derivatives form in the treatment of anxiety and related disorders; bipolar depression and mania; depression; epilepsy and related disorders; epileptogenesis; glucose related disorders; lipid related disorders; migraine; obesity; pain; substance abuse and as neuroprotective agents. The present invention is further directed to a process for the preparation of the novel substituted sulfamide derivatives.
    Type: Grant
    Filed: July 14, 2009
    Date of Patent: August 26, 2014
    Assignee: Janssen Pharmaceutica NV
    Inventors: David F. McComsey, Michael H. Parker
  • OCTAHYDRO-CYCLOPENTAPYRROLYL ANTAGONISTS OF CCR2
    Publication number: 20140024646
    Abstract: The present invention comprises compounds of Formula (I). wherein: R1, R2, R3, R4, R5, Z1 and Z2 are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula (I).
    Type: Application
    Filed: July 16, 2013
    Publication date: January 23, 2014
    Applicant: Janssen Pharmaceutica NV
    Inventors: Chaozhong Cai, David F. MCCOMSEY, Zhihua Sui, Fu-An Kang
  • Urotensin II receptor antagonists
    Patent number: 8445514
    Abstract: This invention is directed to a compound of Formula (I): and forms thereof, wherein A, B, E, G, X and L2 are as defined herein and their use as urotensin II receptor antagonists.
    Type: Grant
    Filed: July 14, 2011
    Date of Patent: May 21, 2013
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: William A. Kinney, Edward C. Lawson, Shyamali Ghosh, Diane K. Luci, David F. McComsey
  • Sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
    Patent number: 8084490
    Abstract: The present invention is directed to novel sulfamide and sulfamate derivatives, pharmaceutical compositions containing them and their use in the treatment of epilepsy and related disorders.
    Type: Grant
    Filed: June 16, 2005
    Date of Patent: December 27, 2011
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: David F. McComsey, Michael H. Parker, Allen B. Reitz, Bruce E. Maryanoff
  • UROTENSIN II RECEPTOR ANTAGONISTS
    Publication number: 20110269768
    Abstract: This invention is directed to a compound of Formula (I): and forms thereof, wherein A, B, E, G, X and L2 are as defined herein and their use as urotensin II receptor antagonists.
    Type: Application
    Filed: July 14, 2011
    Publication date: November 3, 2011
    Inventors: William A. Kinney, Edward C. Lawson, Shyamali Ghosh, Diane K. Luci, David F. McComsey
  • Urotensin II receptor antagonists
    Patent number: 8008299
    Abstract: This invention is directed to a compound of Formula (I): and forms thereof, wherein A, B, E, G, X and L2 are as defined herein and their use as urotensin II receptor antagonists.
    Type: Grant
    Filed: June 5, 2008
    Date of Patent: August 30, 2011
    Assignee: Janssen Pharmaceutica, N.V.
    Inventors: William A. Kinney, Edward C. Lawson, Shyamali Ghosh, Diane K. Luci, David F. McComsey
  • Indazolyl-substituted pyrroline compounds as kinase inhibitors
    Patent number: 7855203
    Abstract: The present invention is directed to novel indazolyl-substituted pyrroline compounds of Formula (I): useful as kinase or dual-kinase inhibitors, methods for producing such compounds and methods for treating or ameliorating a kinase or dual-kinase mediated disorder.
    Type: Grant
    Filed: December 13, 2007
    Date of Patent: December 21, 2010
    Assignee: Ortho-McNeil-Janssen Pharmaceuticals, Inc.
    Inventors: Han-Cheng Zhang, Bruce Maryanoff, Kimberly White, Hong Ye, Leonard R. Hecker, David F. McComsey
  • SUBSTITUTED PYRROLINES AS KINASE INHIBITORS
    Publication number: 20100240650
    Abstract: The present invention is directed to novel substituted pyrroline compounds useful as kinase or dual-kinase inhibitors, methods for producing such compounds and methods for treating or ameliorating a kinase or dual-kinase mediated disorder.
    Type: Application
    Filed: May 25, 2010
    Publication date: September 23, 2010
    Inventors: Han-Cheng Zhang, Bruce E. Maryanoff, David F. McComsey, Kimberly White, Hong Ye, Leonard R. Hecker, Bruce Conway, Keith Demarest
  • Substituted pyrroline kinase inhibitors
    Patent number: 7786135
    Abstract: The present invention is directed to novel substituted pyrroline compounds useful as kinase inhibitors and methods for treating or ameliorating a kinase mediated disorder.
    Type: Grant
    Filed: May 17, 2006
    Date of Patent: August 31, 2010
    Assignee: Janssen Pharmaceutica, N.V.
    Inventors: Han-Cheng Zhang, Gee-Hong Kuo, Bruce E. Maryanoff, Hong Ye, David O'Neill, Lan Shen, Keith Demarest, Bruce R. Conway, David F. McComsey
  • Substituted pyrroline kinase inhibitors
    Patent number: 7781450
    Abstract: The present invention is directed to novel substituted pyrroline compounds useful as kinase inhibitors and methods for treating or ameliorating a kinase mediated disorder.
    Type: Grant
    Filed: March 11, 2009
    Date of Patent: August 24, 2010
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Han-Cheng Zhang, Gee-Hong Kuo, Bruce E. Maryanoff, Hong Ye, David O'Neill, Lan Shen, Keith Demarest, Bruce R. Conway, David F. McComsey
  • Substituted pyrrolines as kinase inhibitors
    Patent number: 7759380
    Abstract: The present invention is directed to novel substituted pyrroline compounds useful as kinase or dual-kinase inhibitors, methods for producing such compounds and methods for treating or ameliorating a kinase or dual-kinase mediated disorder.
    Type: Grant
    Filed: May 8, 2007
    Date of Patent: July 20, 2010
    Assignee: Janssen Pharmaceutica, NV
    Inventors: Han-Cheng Zhang, Bruce E. Maryanoff, David F. McComsey, Kimberly White, Hong Ye, Leonard R. Hecker
  • Substituted pyrroline kinase inhibitors
    Patent number: 7705015
    Abstract: The present invention is directed to novel substituted pyrroline compounds useful as kinase inhibitors and methods for treating or ameliorating a kinase mediated disorder.
    Type: Grant
    Filed: March 11, 2009
    Date of Patent: April 27, 2010
    Assignee: Janssen Pharmaceutica, NV
    Inventors: Han-Cheng Zhang, Gee-Hong Kuo, Bruce E. Maryanoff, Hong Ye, David O'Neill, Lan Shen, David F. McComsey
  • NOVEL SUBSTITUTED SULFAMIDE DERIVATIVES
    Publication number: 20100063138
    Abstract: The present invention is directed to novel substituted sulfamide derivatives, pharmaceutical compositions containing said derivatives and the use of said derivatives form in the treatment of anxiety and related disorders; bipolar depression and mania; depression; epilepsy and related disorders; epileptogenesis; glucose related disorders; lipid related disorders; migraine; obesity; pain; substance abuse and as neuroprotective agents. The present invention is further directed to a process for the preparation of the novel substituted sulfamide derivatives.
    Type: Application
    Filed: July 14, 2009
    Publication date: March 11, 2010
    Inventors: David F. McComsey, Michael H. Parker
  • Substituted pyrrolines as kinase inhibitors
    Patent number: 7608634
    Abstract: The present invention is directed to novel substituted pyrroline compounds useful as kinase or dual-kinase inhibitors, methods for producing such compounds and methods for treating or ameliorating a kinase or dual-kinase mediated disorder.
    Type: Grant
    Filed: May 8, 2007
    Date of Patent: October 27, 2009
    Assignee: Janssen Pharmaceutica NV
    Inventors: Han-Cheng Zhang, Bruce E. Maryanoff, David F. McComsey, Kimberly White, Hong Ye, Leonard R. Hecker, Bruce Conway, Keith Demarest
  • SUBSTITUTED PYRROLINE KINASE INHIBITORS
    Publication number: 20090181982
    Abstract: The present invention is directed to novel substituted pyrroline compounds useful as kinase inhibitors and methods for treating or ameliorating a kinase mediated disorder.
    Type: Application
    Filed: March 11, 2009
    Publication date: July 16, 2009
    Inventors: Han-Cheng Zhang, Gee-Hong Kuo, Bruce E. Maryanoff, Hong Ye, David O'Neill, Lan Shen, Keith Demarest, Bruce R. Conway, David F. McComsey
  • SUBSTITUTED PYRROLINE KINASE INHIBITORS
    Publication number: 20090176806
    Abstract: The present invention is directed to novel substituted pyrroline compounds useful as kinase inhibitors and methods for treating or ameliorating a kinase mediated disorder.
    Type: Application
    Filed: March 11, 2009
    Publication date: July 9, 2009
    Inventors: Han-Cheng Zhang, Gee-Hong Kuo, Bruce E. Maryanoff, Hong Ye, David O'Neill, Lan Shen, Keith Demarest, Bruce R. Conway, David F. McComsey
  • Substituted pyrroline kinase inhibitors
    Patent number: 7524858
    Abstract: The present invention is directed to novel substituted pyrroline compounds useful as kinase inhibitors and methods for treating or ameliorating a kinase mediated disorder.
    Type: Grant
    Filed: May 17, 2006
    Date of Patent: April 28, 2009
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Han-Cheng Zhang, Gee-Hong Kuo, Bruce E. Maryanoff, Hong Ye, David O'Neill, Lan Shen, David F. McComsey
  • Urotensin II receptor antagonists
    Publication number: 20080318973
    Abstract: This invention is directed to a compound of Formula (I): and forms thereof, wherein A, B, E, G, X and L2 are as defined herein and their use as urotensin II receptor antagonists.
    Type: Application
    Filed: June 5, 2008
    Publication date: December 25, 2008
    Inventors: William A. Kinney, Edward C. Lawson, Shyamali Ghosh, Diane K. Luci, David F. McComsey